MX2024009448A - Formas cristalinas de un inhibidor de mcl-1. - Google Patents
Formas cristalinas de un inhibidor de mcl-1.Info
- Publication number
- MX2024009448A MX2024009448A MX2024009448A MX2024009448A MX2024009448A MX 2024009448 A MX2024009448 A MX 2024009448A MX 2024009448 A MX2024009448 A MX 2024009448A MX 2024009448 A MX2024009448 A MX 2024009448A MX 2024009448 A MX2024009448 A MX 2024009448A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- mcl
- inhibitor
- amg
- disclosed
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- BJTFTQIBRVBSBH-VCQPVEJUSA-N CO[C@]1(CN2CCN3CCCC[C@@H]3C2)\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 Chemical compound CO[C@]1(CN2CCN3CCCC[C@@H]3C2)\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 BJTFTQIBRVBSBH-VCQPVEJUSA-N 0.000 abstract 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306776P | 2022-02-04 | 2022-02-04 | |
| PCT/US2023/012251 WO2023150249A1 (en) | 2022-02-04 | 2023-02-03 | Crystalline forms of an mcl-1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009448A true MX2024009448A (es) | 2024-08-15 |
Family
ID=85570021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009448A MX2024009448A (es) | 2022-02-04 | 2023-02-03 | Formas cristalinas de un inhibidor de mcl-1. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250115622A1 (enExample) |
| EP (1) | EP4472984A1 (enExample) |
| JP (1) | JP2025505141A (enExample) |
| AU (1) | AU2023216691A1 (enExample) |
| CA (1) | CA3246092A1 (enExample) |
| MX (1) | MX2024009448A (enExample) |
| WO (1) | WO2023150249A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4519271A1 (en) | 2022-05-04 | 2025-03-12 | Gilead Sciences, Inc. | Salts and polymorphs of certain mcl-1 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| JP2021161114A (ja) * | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
-
2023
- 2023-02-03 US US18/730,357 patent/US20250115622A1/en active Pending
- 2023-02-03 CA CA3246092A patent/CA3246092A1/en active Pending
- 2023-02-03 WO PCT/US2023/012251 patent/WO2023150249A1/en not_active Ceased
- 2023-02-03 AU AU2023216691A patent/AU2023216691A1/en active Pending
- 2023-02-03 MX MX2024009448A patent/MX2024009448A/es unknown
- 2023-02-03 JP JP2024545807A patent/JP2025505141A/ja active Pending
- 2023-02-03 EP EP23710498.9A patent/EP4472984A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025505141A (ja) | 2025-02-21 |
| CA3246092A1 (en) | 2023-08-10 |
| US20250115622A1 (en) | 2025-04-10 |
| EP4472984A1 (en) | 2024-12-11 |
| AU2023216691A1 (en) | 2024-07-04 |
| WO2023150249A1 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009448A (es) | Formas cristalinas de un inhibidor de mcl-1. | |
| DOP2021000216A (es) | Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona | |
| SV2002000121A (es) | Compuestos indazol y composiciones farmaceuticas para inhibir la proteina quinasas y metodo para su uso | |
| CO2019012473A2 (es) | Antagonistas del receptor de hidrocarburos de arilo y usos de los mismos | |
| CL2024004051A1 (es) | Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y métodos de uso. | |
| CR8847A (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y usos de los mismos | |
| CR8860A (es) | Compuestos de aminoheteroarilo enantiometricamente puros como inhibidores de proteina quinasa | |
| ECSP088311A (es) | Inhibidores de la pde y combinaciones de los mismos para el tratamiento de trastornos urológicos | |
| ECSP066467A (es) | Formas Polimórficas de 3-(4-amino-1-Oxo-1-3 DIhidroisoindol-2-IL)-Piperidin-2,6-Diona | |
| CL2023000193A1 (es) | Inductores químicos de degradación conjugados con anticuerpo de brm y métodos de estos. | |
| CL2021002656A1 (es) | Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso. | |
| MX2024009650A (es) | Sal cristalina y formas de solvato de murizatoclax (amg 397). | |
| MX2023000501A (es) | Antagonistas del receptor del factor liberador de corticotropina. | |
| AR040130A1 (es) | Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos | |
| CO2025007764A2 (es) | Degradadores de irak4 y usos de los mismos | |
| MX2024013980A (es) | Conjugados de glucocorticoides y anticuerpos contra el factor de necrosis tumoral alfa humano | |
| CO2024017533A2 (es) | Composiciones de genoterapia y métodos de uso de las mismas | |
| CR20240283A (es) | Procesos para la preparación de degradadores selectivos del receptor de estrógeno | |
| PE20191789A1 (es) | Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa | |
| PE20230259A1 (es) | Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso | |
| MX2025015400A (es) | Moduladores positivos del receptor de acetilcolina muscarinico m4 | |
| MX2024012192A (es) | Formas de sal y solvatos de antagonistas de mci-1 | |
| ES2112832T3 (es) | Derivados carbamoilicos. | |
| AR033207A1 (es) | Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac | |
| GT200500319A (es) | Algunos metabolitos derivados de [1,4]diazepino[6,7,1-ij]quinolina y metodos para la preparacion y usos de los mismos. |